440 related articles for article (PubMed ID: 30559259)
21. Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study.
Röth A; Broome CM; Barcellini W; Jilma B; Hill QA; Cella D; Tvedt THA; Yamaguchi M; Lee M; Shafer F; Wardęcki M; Jiang X; Patel P; Joly F; Weitz IC
Eur J Haematol; 2023 Mar; 110(3):280-288. PubMed ID: 36403132
[TBL] [Abstract][Full Text] [Related]
22. Updates on the Diagnosis and Management of Cold Autoimmune Hemolytic Anemia.
Gertz MA
Hematol Oncol Clin North Am; 2022 Apr; 36(2):341-352. PubMed ID: 35282954
[TBL] [Abstract][Full Text] [Related]
23. Current Treatment Options in Cold Agglutinin Disease: B-Cell Directed or Complement Directed Therapy?
Berentsen S; Tjønnfjord GE
Transfus Med Rev; 2022 Oct; 36(4):181-187. PubMed ID: 36127205
[TBL] [Abstract][Full Text] [Related]
24. [Sutimlimab for cold agglutinin disease, a newcomer among complement inhibitors in immunohematology].
Michel M
Rev Med Interne; 2024 May; 45(5):255-257. PubMed ID: 38719668
[No Abstract] [Full Text] [Related]
25. Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study.
Röth A; Barcellini W; Tvedt THA; Miyakawa Y; Kuter DJ; Su J; Jiang X; Hobbs W; Arias JM; Shafer F; Weitz IC
Ann Hematol; 2022 Oct; 101(10):2169-2177. PubMed ID: 35999387
[TBL] [Abstract][Full Text] [Related]
26. Sutimlimab for the Treatment of Cold Agglutinin Disease.
Berentsen S
Hemasphere; 2023 May; 7(5):e879. PubMed ID: 37153870
[TBL] [Abstract][Full Text] [Related]
27. Complement inhibitors to treat IgM-mediated autoimmune hemolysis.
Wouters D; Zeerleder S
Haematologica; 2015 Nov; 100(11):1388-95. PubMed ID: 26521297
[TBL] [Abstract][Full Text] [Related]
28. Monoclonal antibodies for treatment of cold agglutinin disease.
Gelbenegger G; Berentsen S; Jilma B
Expert Opin Biol Ther; 2023 May; 23(5):395-406. PubMed ID: 37128907
[TBL] [Abstract][Full Text] [Related]
29. Autoimmune hemolytic anemia.
Hill A; Hill QA
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):382-389. PubMed ID: 30504336
[TBL] [Abstract][Full Text] [Related]
30. Molecular pharmacology in complement-mediated hemolytic disorders.
Bortolotti M; Barcellini W; Fattizzo B
Eur J Haematol; 2023 Sep; 111(3):326-336. PubMed ID: 37308291
[TBL] [Abstract][Full Text] [Related]
31. How I treat cold agglutinin disease.
Berentsen S
Blood; 2021 Mar; 137(10):1295-1303. PubMed ID: 33512410
[TBL] [Abstract][Full Text] [Related]
32. Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up.
Röth A; Broome CM; Barcellini W; Tvedt THA; Miyakawa Y; D'Sa S; Cella D; Bozzi S; Jayawardene D; Yoo R; Shafer F; Wardęcki M; Weitz IC
Blood Adv; 2023 Oct; 7(19):5890-5897. PubMed ID: 37459203
[TBL] [Abstract][Full Text] [Related]
33. An observational analysis of disease burden in patients with cold agglutinin disease: Results from a large US electronic health record database.
Pham HP; Wilson A; Adeyemi A; Miles G; Kuang K; Carita P; Joly F
J Manag Care Spec Pharm; 2022 Dec; 28(12):1419-1428. PubMed ID: 36427340
[No Abstract] [Full Text] [Related]
34. Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open-label, extension trial.
Gelbenegger G; Jaeger U; Fillitz M; D'Sa S; Cartwright R; Shafer F; Wardecki M; Wang J; Schoergenhofer C; Jilma B
Br J Haematol; 2022 Aug; 198(4):e59-e62. PubMed ID: 35655238
[No Abstract] [Full Text] [Related]
35. Novel Monoclonal Antibody Therapy in a Patient With Treatment-Refractory Warm Autoimmune Hemolytic Anemia.
Tahhan F; Huynh B; Xu P
Cureus; 2022 Jun; 14(6):e26051. PubMed ID: 35747120
[TBL] [Abstract][Full Text] [Related]
36. Novel insights into the treatment of complement-mediated hemolytic anemias.
Berentsen S; Hill A; Hill QA; Tvedt THA; Michel M
Ther Adv Hematol; 2019; 10():2040620719873321. PubMed ID: 31523413
[TBL] [Abstract][Full Text] [Related]
37. Successful Management of Refractory Autoimmune Hemolytic Anemia with Cold Agglutinin Disease with Splenectomy: A Case Report with Review of Literature.
Okamoto S; Urade T; Yakushijin K; Kido M; Kuramitsu K; Komatsu S; Gon H; Yamashita H; Shirakawa S; Tsugawa D; Terai S; Yanagimoto H; Toyama H; Fukumoto T
Kobe J Med Sci; 2023 Jan; 68(1):E30-E34. PubMed ID: 36647084
[TBL] [Abstract][Full Text] [Related]
38. Complement, cold agglutinins, and therapy.
Berentsen S
Blood; 2014 Jun; 123(26):4010-2. PubMed ID: 24970929
[TBL] [Abstract][Full Text] [Related]
39. Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s.
Simmons KT; Chan J; Hussain S; Rose EL; Markham K; Byun TS; Panicker S; Parry GC; Storek M
Clin Immunol; 2023 Jun; 251():109629. PubMed ID: 37149117
[TBL] [Abstract][Full Text] [Related]
40. Complement-mediated hemolysis persists year round in patients with cold agglutinin disease.
Röth A; Fryzek J; Jiang X; Reichert H; Patel P; Su J; Morales Arias J; Broome CM
Transfusion; 2022 Jan; 62(1):51-59. PubMed ID: 34813663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
